Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, had improved progression-free survival with trastuzumab deruxtecan (Enhertu).
Medscape Medical News
…read more
Miami OBGYN Society
A Membership Organization of South Florida Obstetrician-Gynecologists
